Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) had its target price raised by research analysts at Scotiabank from $14.00 to $16.00 in a research report issued on Wednesday. The firm currently has a “sector perform” rating on the specialty pharmaceutical company’s stock. Scotiabank’s price objective suggests a potential upside of 2.30% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Jefferies Group LLC set a $18.00 price objective on Valeant Pharmaceuticals International and gave the company a “buy” rating in a research report on Saturday, May 6th. Guggenheim assumed coverage on Valeant Pharmaceuticals International in a research report on Saturday, June 17th. They set a “buy” rating and a $18.00 price objective on the stock. Mizuho reaffirmed an “underperform” rating and set a $8.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Tuesday, June 20th. Piper Jaffray Companies set a $14.00 price objective on Valeant Pharmaceuticals International and gave the company a “sell” rating in a research report on Wednesday. Finally, HC Wainwright set a $17.00 price objective on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Wednesday. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Valeant Pharmaceuticals International currently has an average rating of “Hold” and a consensus target price of $17.26.

Shares of Valeant Pharmaceuticals International (VRX) traded down 9.08% during trading on Wednesday, reaching $14.22. 29,171,092 shares of the company were exchanged. Valeant Pharmaceuticals International has a 1-year low of $8.31 and a 1-year high of $32.74. The firm’s market capitalization is $4.95 billion. The firm’s 50 day moving average is $16.44 and its 200 day moving average is $13.39.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. The company had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion. During the same quarter last year, the company earned ($0.88) earnings per share. The firm’s revenue for the quarter was down 7.7% compared to the same quarter last year. On average, equities analysts anticipate that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) PT Raised to $16.00” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/09/valeant-pharmaceuticals-international-inc-vrx-pt-raised-to-16-00.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 20,000 shares of the business’s stock in a transaction dated Thursday, May 11th. The stock was acquired at an average cost of $13.90 per share, for a total transaction of $278,000.00. Following the completion of the transaction, the director now directly owns 70,572 shares of the company’s stock, valued at $980,950.80. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.87% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Gruss & Co. Inc. acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $104,000. Financial Architects Inc boosted its stake in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares during the period. Harbor Advisors LLC acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $110,000. WMS Partners LLC acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $116,000. Finally, Brave Asset Management Inc. acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $119,000. Institutional investors and hedge funds own 51.14% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.